Key result
Tranilast and low-dose losartan significantly blunted the increase in left ventricular weight (P<0.05) and fibrosis, and tranilast improved survival (P=0.029) without lowering blood pressure.
Why the study?
Does inhibition of TGFbeta1 with tranilast or low-dose losartan attenuate left ventricular fibrosis and improve survival in hypertensive TGR(mRen2)27 rats?
Population
4-week-old male hypertensive TGR(mRen2)27 (Ren2) rats
Comparison
Tranilast or low-dose losartan for 12 weeks vs Normal food and Sprague-Dawley control rats
Design
Preclinical
Follow-up
12 weeks
Authors
Loading...
TGFβ inhibition may blunt fibrosis and extend survival in angiotensin-dependent hypertension models; leaves open human translation.
Does inhibition of TGFbeta1 with tranilast or low-dose losartan attenuate left ventricular fibrosis and improve survival in hypertensive TGR(mRen2)27 rats?
Absolute Event Rate: 2.7% vs 3.1%
p-value: p=<0.05
Chronic inhibition of TGFbeta1 expression attenuates left ventricular hypertrophy and fibrosis and improves survival in an angiotensin II-dependent hypertension model, independent of blood pressure lowering.
Pinto et al. (2000) studied Angiotensin II-dependent hypertension (n=74). Tranilast or low-dose losartan vs. Normal food (untreated Ren2 rats) and Sprague-Dawley controls was evaluated on Left ventricular weight (mg/g body wt) (p=<0.05). Tranilast and low-dose losartan significantly blunted the increase in left ventricular weight (P<0.05) and fibrosis, and tranilast improved survival (P=0.029) without lowering blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: